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Abstract 
Review on t(6;9)(p22;q34) DEK/NUP214 in 
Childhood, with data on clinics, and the genes 
involved. 
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Clinics and pathology 
Disease 
Acute myeloid leukemias 1238 (AML) and 
myelodysplastic syndromes (MDS) 
Phenotype/cell stem origin 
t(6;9)(p22;q34) is a rare subtype of pediatric AML 
earlier only described in small series and case reports 
(Gupta, et al 2010, Ishiyama, et al 2012, Slovak, et 
al 2006). Two large studies both published in 2014 
described the clinical, morphologic, and genetic 
characteristics: the I-BFM-study including 62 
children of which 54 was diagnosed as AML and 8 
as MDS, and the COG study investigating 48 
children all diagnosed as AML (Sandahl, et al 2014, 
Tarlock, et al 2014). This review is based upon the 
110 children from these two series. There are no 
pediatric studies of stem cell origin. AML in children 
with t(6;9) is associated with French-American-
British (FAB) type M2 (44%) and FAB type M4 
(25%) (Sandahl, et al 2014, Tarlock, et al 2014). 
Epidemiology 
The t(6;9)(p22;q34) was first described in a pediatric 
patient in 1982 (Kaneko, et al 1982). It is rare, found 
in only about 1% of all pediatric AML (Sandahl, et 
al 2014, Slovak, et al 2006, Tarlock, et al 2014) and 
associated with late onset with a median age 11 years 
and no patients below 2 years of age (Sandahl, et al 
2014, Tarlock, et al 2014). There is an equal sex 
distribution with 53% males. 
Cytology 
Basophilia is common in adults with t(6;9). In the I-
BFM study, peripheral blood smears from 11 children 
and bone marrow smears from 15 children with 
t(6;9)(p22;q34) were evaluable for central review 
(Sandahl, et al 2014).  
All had mild to moderate bilinear dysplasia. 
Basophils were present in five patients (33%), four of 
which had 2% basophils, one patient (6%) had 1% 
basophils, none had > 2%.  
From the remaining 47 AML patients, reports on 
basophils were available in 16 cases; four patients 
had 1-2% basophils in BM smears, one had 0.4%, and 
no basophils were reported in the remaining 11. No 
Auer rods were seen in this reviewed pediatric series. 
Pseudo-Pelger cells were found in all reviewed 
material. Furthermore, almost all had tadpole blasts 
and many have bilobar blasts, both characteristic of 
AML-M3. However no patients were classified as 
FAB M3. 
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BM biopsies from pediatric t(6;9) AML illustrating 
morphologic characteristics A Pseudo-Pelger-Hüet anomaly 
tadpole blasts. Illustration from central review by Gitte 
Kerndrup (2013) 
Treatment 
It has been suggested that Hematopoietic stem cell 
transplantation (HSCT) in first complete remission 
may improve outcome. In the I-BFM-study, the 5-
year event-free survival was improved among 
patients treated the HSCT in CR1 compared with 
chemotherapy alone (68% vs. 18%; P<0.01) but it 
did not effect the OS (68% vs. 54%; P=0.48). In the 
COG study those who received HSCT in CR1 or 
CR2 had a survival of 60% vs. 21% in those treated 
with chemotherapy alone (Tarlock, et al 2014). 
Prognosis 
Complete remission rate is significantly lower 
compared with pediatric AML patients without 
t(6;9)(Tarlock, et al 2014), but reported CR rates 
varied between 67 and 93%. (Sandahl, et al 2014, 
Tarlock, et al 2014) Furthermore, t(6;9) was 
associated with high risk of relapse 57%-64%, low 
5-year EFS of 32%  and 5-year OS around 
45%(Sandahl, et al 2014, Tarlock, et al 2014). 
The outcome seems better among pediatric t(6,9) 
patients compared with adults (Slovak, et al 
2006).(Ishiyama, et al 2012, Slovak, et al 2006). 
Among t(6;9) patients FLT3-ITD had a non-
significant negative influence on survival with a 5-
year overall survival compared with non-FLT3-ITD 
(22% versus 62%; p=0.13) in the I-BFM study 
(Sandahl, et al 2014). The OS in the COG study was 
in contrast higher with FLT3-ITD than without (40% 
vs. 27%; p>0.9) which may be explained by FLT3-
ITD being allocated to hematopoietic stem cell 
transplantation (HSCT) (Sandahl, et al 2014, 
Tarlock, et al 2014) 
Genetics 
The t(6;9) is often associated with FLT3-ITD  
reported in 42% to 69% (Sandahl, et al 2014, Slovak, 
et al 2006, Tarlock, et al 2014). 
In the I-BFM study, the gene expression profile was 
analyzed in 297 pediatric AML patients including 
eight t(6;9) AML cases. The t(6,9) cases had a 
significant signature with high expression levels of 
HOXA and the HOXB (HOXB2, (HOXB3, 
(HOXB4, HOXB5, HOXB6, HOXB8, and HOXB9) 
genes described previously (Hollink, et al 2011) but 
also with high expression of HIST2H4A, PRDM2 
(RIZ), SESN1, and EYA3 (Sandahl, et al 2014). 
Cytogenetics 
Cytogenetics morphological 
The translocation is easily detected by conventional 
karyotyping, only 4/62 pediatric cases were 
discovered solely by FISH or PCR (Sandahl, et al 
2014). 
Additional anomalies 
t(6;9)(p22;q34) often presents as the sole cytogenetic 
abnormality (81%). (Gupta, et al 2010). Additional 
abnormalities are described in 12-19%. (Sandahl, et 
al 2014) Recurrent aberrations in addition to t(6;9) 
have been described in 19% with loss of 
chromosome Y in three boys and trisomy 8 and 
trisomy 13 each present in three cases, either alone 
or combined  (Sandahl, et al 2014). 
Genes involved and 
proteins 
DEK (DEK proto-oncogene) 
Location 
6p22.3 
Protein 
375 amino-acids; DEK contains acidic domains 
(Asp/Glu-rich), a SAF/SAP box, a nuclear 
localisation signal; and other DNA binding domains. 
Highly conserved nuclear factor; chromatin 
remodeling protein, essential for heterochromatin 
integrity; DEK localizes preferentially at sites 
proximal to the promoters of expressed genes; acts 
as a repressor of transcription by interfering with 
histone acetyl-transferases and as an activator of 
transcription by stimulating the binding of TFAP2A 
(the activator protein AP2-alpha) to its target DNA 
sequences; DEK introduces super-coils into circular 
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DNA (in Oancea et al., 2010). DEK is a regulator of 
stem and progenitor cells and is upregulated in a 
number of neoplasms (breast cancer, chronic 
lymphocytic leukemia, small cell lung carcinoma, 
Merkel cell carcinoma, melanoma, glioblastoma, 
retinoblastoma, cervical, and bladder cancers) 
(review in Riveiro-Falkenbach and Soengas, 2010); 
CEBPA and DEK coordinately activate myeloid 
gene expression (Koleva et al., 2012); DEK is an 
estrogen receptor alpha (ESR1) target gene (Privette 
Vinnedge et al., 2012). DEK expression modulates 
ATM and DNA-dependent protein kinase signaling, 
and contributes to DNA repair (Kavanaugh et al., 
2011). 
NUP214 (nucleoporin 214kDa) 
Location 
9q34.13 
Note 
The previous name of NUP214 was CAN. 
Protein 
2090 amino acids; contains dimerization domains (2 
leucine zippers) and FG repeats; forms homodimers; 
the C-terminus is essential; the N-terminus is 
involved in mRNA export (Köser et al., 2005). 
Nuclear membrane localisation (cytoplasmic face of 
nucleopore); component of the nuclear pore 
complex; involved in nucleo-cytoplasmic transport. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' DEK - 3' NUP214 on der(6); head to tail 
DEK/NUP214 fusion gene (SET/NUP214 
exceptional); breakpoint clusters in a single intron of 
8 kb (ICB9: 'intron containing breakpoint 9') in 
NUP214, and in a single intron (of 12 kb) as well 
(ICB6) in DEK. 
Transcript 
5.5 kb RNA; no NUP214-DEK reciprocal transcript 
on chromosome 9. 
Detection 
RNA-PCR. 
Fusion protein 
Description 
165 kDa; N-term with almost the entire DEK protein 
fused to the C-terminal two-thirds of the  
NUP214 protein. 
Expression / Localisation 
Nuclear localisation. 
References 
Gupta M, Ashok Kumar J, Sitaram U, Neeraj S, Nancy A, 
Balasubramanian P, Abraham A, Mathews V, Viswabandya 
A, George B, Chandy M, Srivastava A, Srivastava VM. The 
t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study 
of 16 cases. Cancer Genet Cytogenet. 2010 
Dec;203(2):297-302 
Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters 
ST, Pratcorona M, Abbas S, Kuipers JE, van Galen JF, 
Beverloo HB, Sonneveld E, Kaspers GJ, Trka J, Baruchel 
A, Zimmermann M, Creutzig U, Reinhardt D, Pieters R, Valk 
PJ, Zwaan CM. NUP98/NSD1 characterizes a novel poor 
prognostic group in acute myeloid leukemia with a distinct 
HOX gene expression pattern. Blood. 2011 Sep 
29;118(13):3645-56 
Ishiyama K, Takami A, Kanda Y, Nakao S, Hidaka M, 
Maeda T, Naoe T, Taniguchi S, Kawa K, Nagamura T, 
Tabuchi K, Atsuta Y, Sakamaki H. Prognostic factors for 
acute myeloid leukemia patients with t(6;9)(p23;q34) who 
underwent an allogeneic hematopoietic stem cell transplant. 
Leukemia. 2012 Jun;26(6):1416-9 
Kaneko Y, Rowley JD, Maurer HS, Variakojis D, Moohr JW. 
Chromosome pattern in childhood acute nonlymphocytic 
leukemia (ANLL). Blood. 1982 Aug;60(2):389-99 
Sandahl JD, Coenen EA, Forestier E, Harbott J, Johansson 
B, Kerndrup G, Adachi S, Auvrignon A, Beverloo HB, 
Cayuela JM, Chilton L, Fornerod M, de Haas V, Harrison 
CJ, Inaba H, Kaspers GJ, Liang DC, Locatelli F, Masetti R, 
Perot C, Raimondi SC, Reinhardt K, Tomizawa D, von 
Neuhoff N, Zecca M, Zwaan CM, van den Heuvel-Eibrink 
MM, Hasle H. t(6;9)(p22;q34)/DEK-NUP214-rearranged 
pediatric myeloid leukemia: an international study of 62 
patients. Haematologica. 2014 May;99(5):865-72 
Slovak ML, Gundacker H, Bloomfield CD, Dewald G, 
Appelbaum FR, Larson RA, Tallman MS, Bennett JM, 
Stirewalt DL, Meshinchi S, Willman CL, Ravindranath Y, 
Alonzo TA, Carroll AJ, Raimondi SC, Heerema NA. A 
retrospective study of 69 patients with t(6;9)(p23;q34) AML 
emphasizes the need for a prospective, multicenter initiative 
for rare 'poor prognosis' myeloid malignancies. Leukemia. 
2006 Jul;20(7):1295-7 
Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi 
SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, 
Gamis AS, Meshinchi S. Acute myeloid leukaemia (AML) 
with t(6;9)(p23;q34) is associated with poor outcome in 
childhood AML regardless of FLT3-ITD status: a report from 
the Children's Oncology Group. Br J Haematol. 2014 
Jul;166(2):254-259 
This article should be referenced as such: 
Hasle H, Sandahl JD. t(6;9)(p22;q34) DEK/NUP214 in 
Childhood. Atlas Genet Cytogenet Oncol Haematol. 
2017; 21(8):303-305. 
  
